These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 12517829)

  • 1. In vitro activities of voriconazole, posaconazole, and four licensed systemic antifungal agents against Candida species infrequently isolated from blood.
    Pfaller MA; Diekema DJ; Messer SA; Boyken L; Hollis RJ; Jones RN;
    J Clin Microbiol; 2003 Jan; 41(1):78-83. PubMed ID: 12517829
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro susceptibilities of rare Candida bloodstream isolates to ravuconazole and three comparative antifungal agents.
    Pfaller MA; Diekema DJ; Messer SA; Boyken L; Hollis RJ; Jones RN
    Diagn Microbiol Infect Dis; 2004 Feb; 48(2):101-5. PubMed ID: 14972378
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of Etest method for determining fluconazole and voriconazole MICs for 279 clinical isolates of Candida species infrequently isolated from blood.
    Maxwell MJ; Messer SA; Hollis RJ; Boyken L; Tendolkar S; Diekema DJ; Pfaller MA
    J Clin Microbiol; 2003 Mar; 41(3):1087-90. PubMed ID: 12624034
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Results from the ARTEMIS DISK Global Antifungal Surveillance Study, 1997 to 2007: a 10.5-year analysis of susceptibilities of Candida Species to fluconazole and voriconazole as determined by CLSI standardized disk diffusion.
    Pfaller MA; Diekema DJ; Gibbs DL; Newell VA; Ellis D; Tullio V; Rodloff A; Fu W; Ling TA;
    J Clin Microbiol; 2010 Apr; 48(4):1366-77. PubMed ID: 20164282
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [In vitro activity of fluconazole, voriconazole and posaconazole against Candida spp].
    Rubio Calvo MC; Gil J; Ramírez de Ocáriz I; Benito R; Rezusta A
    Rev Esp Quimioter; 2003 Jun; 16(2):227-32. PubMed ID: 12973462
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Antifungal susceptibility profiles of Candida species to triazole: application of new CLSI species-specific clinical breakpoints and epidemiological cutoff values for characterization of antifungal resistance].
    Karabıçak N; Alem N
    Mikrobiyol Bul; 2016 Jan; 50(1):122-32. PubMed ID: 27058336
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Trends in species distribution and susceptibility of bloodstream isolates of Candida collected in Monterrey, Mexico, to seven antifungal agents: results of a 3-year (2004 to 2007) surveillance study.
    González GM; Elizondo M; Ayala J
    J Clin Microbiol; 2008 Sep; 46(9):2902-5. PubMed ID: 18632907
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [In vitro activity of voriconazole and other antifungal agents against clinical isolates of 138 Candida spp].
    Ricciardi AM; Ricciardi R; Danzi M; Mungiguerra M; Pisano L; Marino A
    Infez Med; 2009 Mar; 17(1):24-7. PubMed ID: 19359821
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Wild-type MIC distributions and epidemiological cutoff values for posaconazole and voriconazole and Candida spp. as determined by 24-hour CLSI broth microdilution.
    Pfaller MA; Boyken L; Hollis RJ; Kroeger J; Messer SA; Tendolkar S; Diekema DJ
    J Clin Microbiol; 2011 Feb; 49(2):630-7. PubMed ID: 21159940
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multilaboratory study of epidemiological cutoff values for detection of resistance in eight Candida species to fluconazole, posaconazole, and voriconazole.
    Espinel-Ingroff A; Pfaller MA; Bustamante B; Canton E; Fothergill A; Fuller J; Gonzalez GM; Lass-Flörl C; Lockhart SR; Martin-Mazuelos E; Meis JF; Melhem MS; Ostrosky-Zeichner L; Pelaez T; Szeszs MW; St-Germain G; Bonfietti LX; Guarro J; Turnidge J
    Antimicrob Agents Chemother; 2014; 58(4):2006-12. PubMed ID: 24419346
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro activities of voriconazole (UK-109,496) and four other antifungal agents against 394 clinical isolates of Candida spp.
    Marco F; Pfaller MA; Messer S; Jones RN
    Antimicrob Agents Chemother; 1998 Jan; 42(1):161-3. PubMed ID: 9449278
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro activities of new triazole antifungal agents, posaconazole and voriconazole, against oral Candida isolates from patients suffering from denture stomatitis.
    Marcos-Arias C; Eraso E; Madariaga L; Carrillo-Muñoz AJ; Quindós G
    Mycopathologia; 2012 Jan; 173(1):35-46. PubMed ID: 21842426
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Activities of fluconazole and voriconazole against 1,586 recent clinical isolates of Candida species determined by Broth microdilution, disk diffusion, and Etest methods: report from the ARTEMIS Global Antifungal Susceptibility Program, 2001.
    Pfaller MA; Diekema DJ; Messer SA; Boyken L; Hollis RJ
    J Clin Microbiol; 2003 Apr; 41(4):1440-6. PubMed ID: 12682127
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro susceptibilities of Candida dubliniensis isolates tested against the new triazole and echinocandin antifungal agents.
    Pfaller MA; Messer SA; Gee S; Joly S; Pujol C; Sullivan DJ; Coleman DC; Soll DR
    J Clin Microbiol; 1999 Mar; 37(3):870-2. PubMed ID: 9986880
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro activities of posaconazole, fluconazole, itraconazole, voriconazole, and amphotericin B against a large collection of clinically important molds and yeasts.
    Sabatelli F; Patel R; Mann PA; Mendrick CA; Norris CC; Hare R; Loebenberg D; Black TA; McNicholas PM
    Antimicrob Agents Chemother; 2006 Jun; 50(6):2009-15. PubMed ID: 16723559
    [TBL] [Abstract][Full Text] [Related]  

  • 16. International and multicenter comparison of EUCAST and CLSI M27-A2 broth microdilution methods for testing susceptibilities of Candida spp. to fluconazole, itraconazole, posaconazole, and voriconazole.
    Espinel-Ingroff A; Barchiesi F; Cuenca-Estrella M; Pfaller MA; Rinaldi M; Rodriguez-Tudela JL; Verweij PE
    J Clin Microbiol; 2005 Aug; 43(8):3884-9. PubMed ID: 16081926
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [One-Year Candida Data of the Central Mycology Laboratory: Which Sample, Which Species, How Resistant?].
    Turan D; Aksaray S
    Mikrobiyol Bul; 2022 Jul; 56(3):493-505. PubMed ID: 35960240
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro susceptibility testing of Candida and Aspergillus spp. to voriconazole and other antifungal agents using Etest: results of a French multicentre study.
    Mallié M; Bastide JM; Blancard A; Bonnin A; Bretagne S; Cambon M; Chandenier J; Chauveau V; Couprie B; Datry A; Feuilhade M; Grillot R; Guiguen C; Lavarde V; Letscher V; Linas MD; Michel A; Morin O; Paugam A; Piens MA; Raberin H; Tissot E; Toubas D; Wade A
    Int J Antimicrob Agents; 2005 Apr; 25(4):321-8. PubMed ID: 15784312
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Epidemiology and Antifungal Susceptibility of
    Badiee P; Boekhout T; Haddadi P; Mohammadi R; Ghadimi-Moghadam A; Soltani J; Zarei Mahmoudabadi A; Ayatollahi Mousavi SA; Najafzadeh MJ; Diba K; Salimi-Khorashad AR; Amin Shahidi M; Ghasemi F; Jafarian H
    Microbiol Spectr; 2022 Dec; 10(6):e0245322. PubMed ID: 36445122
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Twelve years of fluconazole in clinical practice: global trends in species distribution and fluconazole susceptibility of bloodstream isolates of Candida.
    Pfaller MA; Diekema DJ;
    Clin Microbiol Infect; 2004 Mar; 10 Suppl 1():11-23. PubMed ID: 14748799
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.